Clinical Trial Update: Safety and Efficacy Study of Pirfenidone to Treat Idiopathic Pulmonary Fibrosis(IPF) [Phase 2]

View source ↗

Summary

This document describes a Phase 2 safety and efficacy study of pirfenidone to treat idiopathic pulmonary fibrosis (IPF). The status of the trial is UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• PIRFENIDONE (pirfenidone)

Snippet

Sponsor: Beijing Kawin Technology Share-Holding Co., Ltd. | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: UNKNOWN